Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Convergence 2024 Preview: Key Business Takeaways

Carina Stanton  |  October 8, 2024

Ms. Ellis

The second portion of the session will be with Nancy Ellis, MBA, MHA, CHE, CRHC, CRMS, CPMA, practice administrator for Piedmont Arthritis Clinic and past president of the National Organization of Rheumatology Management. She will share her perspectives on coding for accurate reimbursement, especially to alert practices to coding errors that could be impacting their practice, such as defaulting to unspecified codes. “This may seem harmless, but more and more payers are putting billing edits in place to possibly deny those claims,” Ms. Ellis cautions.

She will also discuss how a practice can invest in ongoing training and certifications for their coders. “There are so many changes that can happen, it is imperative to have up-to-date information and well-seasoned coders.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Start Planning Now

With only one month until ACR Convergence 2024, now is a good time to build your schedule to make sure you can capture as much knowledge as possible at the meeting. Both sessions discussed here are offered in person and on-demand. Explore these and other sessions in the business of rheumatology track and start planning your schedule for the meeting. View the full schedule to learn more about the education offered at ACR Convergence 2024.

Carina Stanton is a freelance science journalist based in Denver.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergencePractice ManagementPractice Support Tagged with:ACR Convergence 2024

Related Articles

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    The 2018 ACR/ARHP Annual Meeting Program Preview

    September 20, 2018

    Save the date for the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Connect with your colleagues for an unmatched educational experience featuring exceptional sessions by leading rheumatology experts. The ACR/ARHP Annual Meeting is your gateway to global rheumatology education. With more than 450 sessions—including The Great Debate—the meeting provides boundless opportunities for professional development,…

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences